Newsfiscal.ai
Wall Street Analysts Downgrade EyePoint Pharmaceuticals Following Clinical Trial Results
· Published
Article summary
Multiple financial institutions, including JPMorgan, Mizuho Securities, and Guggenheim, downgraded EyePoint Pharmaceuticals' stock rating following the company's recent clinical trial failure.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…